Latest Market Expansion News

Vmoto Limited posted its strongest half-year sales ever with $35.7 million revenue and a 140% surge in unit sales, underpinned by new global partnerships and international market growth.

Orthocell posts record FY26 revenue growth driven by expanding US and international sales of its collagen medical devices, while investing ahead in manufacturing capacity and product pipeline.

Simonds Group delivered a record net profit after tax of $10.5 million for FY26, driven by a 9.5% revenue rise to $729.1 million and strategic expansion including a Western Australia joint venture.

Audeara Limited delivered record FY26 revenue of $4.45 million, driven by a 45% surge in Australian wholesale sales and progress in AI audio licensing with OPTEK Microelectronics. The company narrowed its loss and advanced Auracast deployments across retirement villages and education sectors.

Orbital Corporation has broadened its customer base and product lineup, positioning itself to capture growth in defence and commercial UAV markets with $3.2 million in expected sales for Q1 FY2027.

xReality Group (ASX: XRG) delivered a standout FY26 with total income up 43% to $20 million and EBITDA surging to $3.8 million, backed by rapid expansion of its Operator XR defence training platform.

Volt Group’s HY26 results showcase a surge in revenue and cashflow, powered by the 4D Delta acquisition and strong performances across its subsidiaries.

RemSense Technologies reported a 27% revenue decline in FY2026 to $2.49 million due to project timing and economic uncertainty but secured major Tier-1 contracts and raised $1.21 million to fund technology development.

Jatcorp Limited's FY26 results show a 23% revenue increase to $38.9 million but a 41% larger loss attributable to owners. The company faces a material uncertainty over going concern despite improved statutory NPAT.

Boresight Ltd (ASX: BST) recorded a 46% increase in revenue to $6.38 million for FY26, driven by global sales expansion and strategic investments including an $8 million IPO. Despite this growth, the company posted a $6.66 million net loss, largely due to increased operational expenses and significant share-based payments.

Bio-Gene Technology narrowed its loss to $2.33 million in FY26 while progressing key toxicity studies for Flavocide and securing a commercial foothold for Qcide in Japan. The company bolstered its balance sheet with a $3.275 million capital raise to fund ongoing development and production scale-up.

Constellation Technologies (ASX:CT1) reported a 5% revenue decline to $1.71 million and a $458,246 net loss for FY26, weighed down by delayed hardware deployments and increased expenses. Recurring subscription revenue grew 22%, reflecting ongoing customer engagement.